News
Weight-loss supplements recommended by influencers on social mead are generally ineffective for weight loss, but do have some benefits.
I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...
Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...
While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results